SIERRA LEONE DROPS TREASON CHARGES AGAINST EX-PRESIDENT ERNEST KOROMA. (PHOTO).
Researchers in the Democratic Republic of Congo said on Tuesday they have started enrolling participants in a trial testing Gilead Sciences' experimental antiviral obeldesivir as a post-exposure treatment for the ongoing Bundibugyo Ebola outbreak in DR Congo and Uganda.
DR Congo's National Institute for Biomedical Research among other international agencies are leading the trial in Ituri province, the epicentre of the outbreak.
The trial is designed to assess whether post-exposure treatment can reduce the risk of developing Ebola infection after contact with the virus, Reuters reported.
The study aims to enroll about 1,000 people aged 12 years and older, who had high-risk exposure to a confirmed Ebola case within the previous five days but have not developed symptoms.
Participants will be monitored daily for 21 days, with a final follow-up at 42 days.
Comments
Post a Comment